Anamorelin China’s launch progress and generic drug price overview

Anamulin (trade name:Adlumiz), as a new cancer cachexia treatment drug, has received widespread attention around the world in recent years. However, for Chinese cancer patients, anamorelin has not yet been officially launched in the country, which undoubtedly brings some trouble to patients who are in urgent need of this drug.

Anamulin was first approved for marketing in Japan in January 2021. It is used to treat cancer cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, colorectal cancer and other malignant tumors. The drug activates the corresponding receptors by simulating ghrelin, thereby improving the patient's appetite, increasing weight and muscle mass, and improving quality of life. In Japan, anamorelin has achieved remarkable therapeutic effects, bringing new hope to many patients with cancer cachexia.

However, in China, the market situation of anamulin is different. Although domestic patients are in urgent need of anamorelin, patients cannot purchase it directly in China because the drug has not yet been officially launched in China. For patients who urgently need Anamorelin, they can only purchase it through overseas channels. Currently, there are two main types of Anamorelin available on the market: one is the Japanese original version, which is relatively expensive, about more than 6,000 yuan; the other is the imitation version from Laos, which is relatively cheap, usually between 3 and 4,000 yuan. Although the generic version is more advantageous in terms of price, patients still need to be cautious when choosing and make sure to purchase through formal channels to ensure product quality.

It is worth noting that the progress of Anamorelin’s domestic launch has always been the focus of patients’ attention. Although there is currently no clear timetable for the launch, with the continuous opening of the domestic pharmaceutical market, it is only a matter of time before Anamorelin will be launched in the country. Once Anamorelin is launched in China, it will provide more treatment options for domestic cancer cachexia patients, reduce their financial burden, and improve their quality of life.

In summary, anamorelin, as a new cancer cachexia treatment drug, has achieved significant therapeutic effects worldwide. Although it has not yet been launched in China, domestic patients can still purchase it through some formal channels. Patients should ask for the drug version according to their needs.